Concepedia

Huaibao Feng

HF

Statistics

Publications

19

Citations

2.8K

H-Index

16

Active since

2007

Affiliations

Janssen (United States)(Current)

Emory University

Levine Cancer Institute

Carolinas Healthcare System

University of Calgary

Huaibao Feng is an author at Janssen (United States) specializing in medicine, multiple myeloma, and multiple myeloma therapy.

Publications per year

2007–2020

19

Publications

19

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 917 citations

, , +15

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

, , +14

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood · 2016 · 404 citations · Full text

, , +14

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

Saad Z. Usmani, Hareth Nahi, Torben Plesner et al. · The Lancet Haematology · 2020 · 109 citations

, , +14

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Philippe Moreau, Ievgenii Karamanesht, Maryna Kyselyova et al. · Clinical Pharmacokinetics · 2012 · 85 citations

, , +14

1–5 of 19